Search results
Results From The WOW.Com Content Network
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
CEO, Sanofi. Term. September 2019-. Predecessor. Olivier Brandicourt. Children. 3. Paul Hudson (born 14 October 1967) [ 2] is a British businessman, and the chief executive (CEO) of Sanofi, the world's fifth largest pharmaceutical company by prescription drug sales. [ 3]
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
If you believe all the rumors and leaks, French pharmaceutical group Sanofi-Aventis (SNY) and U.S. biotechnology company Genzyme (GENZ) should have reached a merger agreement by now. Instead ...
Within this group, Pasteur Mérieux Connaught changes its name to Aventis Pasteur. 2004: merger of Aventis with and into Sanofi. The new Sanofi-Aventis Group becomes the world's 3rd largest pharmaceutical company, behind Pfizer and GlaxoSmithKline. Aventis Pasteur, the vaccine division of the Sanofi-Aventis Group, changes its name to Sanofi ...
The news comes months after Sanofi announced it was reviewing "separation scenarios" for the unit in a bid to focus on its core innovative drugs business. Sanofi's consumer healthcare spin-off ...
French pharmaceutical company Sanofi-Aventis (SNY), which has been unsuccessful recently in its courtship of U.S. giant biotech Genzyme (GENZ), announced another setback today. Sanofi said a late ...
Telithromycin is the first ketolide antibiotic to enter clinical use and is sold under the brand name of Ketek. It is used to treat community acquired pneumonia of mild to moderate severity. After significant safety concerns, the US Food and Drug Administration sharply curtailed the approved uses of the drug in early 2007.